Cleaved-F2RL3 (G48) Antibody

What is F2RL3 and how does the Cleaved-F2RL3 (G48) Antibody differ from standard F2RL3 antibodies?

F2RL3 (also known as PAR4) is a member of the protease-activated receptor family and belongs to the larger family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. Unlike standard F2RL3 antibodies that detect the whole protein, Cleaved-F2RL3 (G48) Antibody specifically recognizes the activated form of PAR4 resulting from proteolytic cleavage adjacent to glycine at position 48 (G48). This antibody detects endogenous levels of the fragment of activated PAR4 protein, making it useful for studying receptor activation states rather than mere expression levels .

What is the molecular basis for PAR4 activation that enables detection by Cleaved-F2RL3 (G48) Antibody?

PAR4 is activated through proteolytic cleavage of its extracellular amino terminus by proteases such as thrombin or trypsin. This cleavage generates a new N-terminus that functions as a tethered ligand, activating the receptor through intramolecular binding. The Cleaved-F2RL3 (G48) Antibody recognizes epitopes exposed after this cleavage event adjacent to G48, allowing researchers to specifically detect the activated form of the receptor. Recent structural studies have shown that upon activation, the PAR4 dimer interface (M203 4.52-L213 4.62) packs more tightly, with deuterium uptake decreasing from 6.4% to 3.4%, suggesting conformational changes that may expose the epitope recognized by the antibody .

What are the validated applications for Cleaved-F2RL3 (G48) Antibody and their recommended protocols?

The Cleaved-F2RL3 (G48) Antibody has been validated for Western Blot (WB) and ELISA applications. For optimal results, the following working dilutions are recommended:

While these are the validated applications, researchers should note that optimal working dilutions should be determined experimentally for each specific research context .

How should samples be prepared for optimal detection of cleaved PAR4 using this antibody?

For optimal detection of cleaved PAR4, samples should be prepared with careful consideration of the following factors:

• Preservation of protein integrity: Use protease inhibitors during sample preparation to prevent unwanted proteolytic degradation.

• Appropriate activation conditions: If studying PAR4 activation, ensure proper thrombin or trypsin treatment conditions are used.

• Buffer considerations: The antibody is supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Sample buffers should be compatible with downstream applications.

• Denaturing conditions for Western Blot: Ensure complete denaturation for WB applications to expose the epitope fully.

When comparing activated versus non-activated samples, it's important to maintain identical protein extraction and handling procedures to ensure that differences observed are due to receptor activation rather than sample preparation artifacts .

How can Cleaved-F2RL3 (G48) Antibody be used to study conformational changes in PAR4 activation?

Cleaved-F2RL3 (G48) Antibody provides a powerful tool for investigating the conformational changes associated with PAR4 activation. Recent research using hydrogen/deuterium exchange mass spectrometry has revealed that PAR4 activation involves significant structural rearrangements, including:

• Tighter packing of the dimer interface (M203 4.52-L213 4.62), where deuterium uptake decreased from 6.4% to 3.4% upon thrombin cleavage.

• Increased solvent accessibility of intracellular loop 2 (ICL2, H180PLRA 184), with H/D exchange increasing from 41% to 45% upon activation.

• Changes in the hinge region near helix 8 (amino acids Y 342 and VSAEF 347), where deuteration increased from 41% to 50%.

Researchers can use the Cleaved-F2RL3 (G48) Antibody in conjunction with techniques such as co-immunoprecipitation or proximity ligation assays to investigate how these conformational changes affect interactions with downstream signaling partners .

What is the relationship between F2RL3 methylation and protein expression/activation, and how can this antibody contribute to such studies?

F2RL3 methylation has emerged as a promising biomarker for current and lifetime smoking exposure. Studies have demonstrated pronounced differences in methylation of the F2RL3 gene (also known as PAR-4) in blood DNA according to smoking exposure. To investigate the relationship between F2RL3 methylation and protein activation:

• Compare DNA methylation patterns using techniques like MALDI-TOF mass spectrometry

• Correlate methylation data with protein activation levels as detected by Cleaved-F2RL3 (G48) Antibody

• Examine how different degrees of smoking exposure affect both methylation and protein activation

This antibody can help determine whether altered gene methylation translates to functional changes in protein activation, potentially linking epigenetic modifications to altered platelet function in smokers .

How can researchers validate the specificity of the Cleaved-F2RL3 (G48) Antibody in their experimental system?

To validate antibody specificity, researchers should implement the following approaches:

• Peptide blocking experiments: Pre-incubate the antibody with excess synthetic peptide used as the immunogen (amino acids 29-78 of human PAR4) before application to samples. Specific signals should be significantly reduced or eliminated.

• Genetic validation: Use PAR4/F2RL3 knockout or knockdown models as negative controls. Similar to the approach described in the cleaved-Caspase-3 antibody studies, genetic ablation provides the most definitive control for antibody specificity .

• Activation controls: Compare samples with and without thrombin/trypsin treatment to confirm that the antibody detects only the cleaved form.

• Cross-reactivity assessment: If working with non-human models, validate cross-reactivity with the species of interest, as some product information indicates human specificity while others suggest reactivity with mouse and rat samples .

What are the most common misinterpretations of data obtained using Cleaved-F2RL3 (G48) Antibody and how can they be avoided?

Based on lessons learned from similar antibodies targeting activated proteins, researchers should be aware of these potential misinterpretations:

• Assuming single protein specificity: As demonstrated with the cleaved-Caspase-3 antibody in Drosophila research, antibodies raised against activated proteins may recognize multiple substrates requiring the same activation mechanism. Researchers should consider that Cleaved-F2RL3 (G48) Antibody might recognize additional proteins that undergo similar proteolytic processing .

• Confusing expression with activation: A stronger signal may indicate increased activation rather than increased expression of the underlying receptor. To distinguish between these possibilities, parallel experiments with antibodies detecting total PAR4 should be conducted.

• Overlooking cross-reactivity: The antibody may detect cleaved products from related receptors, especially other PAR family members. Appropriate controls should be included to rule out cross-reactivity.

• Neglecting post-translational modifications: Other modifications may influence epitope accessibility. Researchers should consider how phosphorylation or glycosylation might affect antibody binding to the cleaved receptor .

What are the critical storage and handling considerations for maintaining Cleaved-F2RL3 (G48) Antibody activity?

To maintain optimal antibody performance, adhere to these storage and handling guidelines:

The antibody is supplied as a liquid in PBS containing these stabilizing agents, and proper storage is critical for maintaining its specificity and sensitivity in research applications .

How can researchers optimize Western blot protocols specifically for Cleaved-F2RL3 (G48) Antibody?

For optimal Western blot results with Cleaved-F2RL3 (G48) Antibody, consider these methodological adjustments:

• Sample preparation:

  • Include positive controls (thrombin-treated samples)

  • Use phosphatase inhibitors to preserve post-translational modifications

  • Consider non-reducing conditions if disulfide bonds affect epitope structure

• Blocking optimization:

  • Test BSA vs. non-fat dry milk as blocking agents

  • Consider 3-5% blocking agent concentration

  • Optimize blocking time (1-2 hours at room temperature or overnight at 4°C)

• Antibody incubation:

  • Start with 1:1000 dilution and adjust based on signal strength

  • Incubate primary antibody overnight at 4°C for maximum sensitivity

  • Consider adding 0.1% Tween-20 to reduce background

• Detection optimization:

  • Use high-sensitivity ECL substrates for detecting low abundance cleaved proteins

  • Consider longer exposure times initially

• Troubleshooting high background:

  • Increase washing duration and frequency

  • Decrease primary antibody concentration

  • Pre-absorb antibody with non-specific proteins

The validation images seen in some product descriptions show clear detection of cleaved PAR4 in cell lines including HepG2, Jurkat, HeLa, HT-29, and LOVO cells, suggesting these could serve as positive controls .

How might Cleaved-F2RL3 (G48) Antibody contribute to understanding the role of PAR4 in diseases beyond platelet activation?

While PAR4 has been primarily studied in platelets, emerging research suggests broader roles that could be investigated using Cleaved-F2RL3 (G48) Antibody:

• Cancer biology: PAR family receptors have been implicated in tumor progression. The antibody could help investigate whether PAR4 activation status correlates with cancer aggressiveness or treatment response.

• Inflammatory disorders: Given that thrombin signaling connects coagulation with inflammation, investigating PAR4 activation in inflammatory conditions could reveal new therapeutic targets.

• Neurodegenerative diseases: Protease signaling plays roles in neurodegeneration. Examining PAR4 activation in neural tissues may uncover previously unknown disease mechanisms.

• Cardiovascular disorders beyond thrombosis: Beyond its known role in platelet activation, PAR4 may contribute to vascular remodeling and atherosclerosis progression.

For these applications, researchers might need to optimize protocols for immunohistochemistry or flow cytometry, although these applications have not yet been extensively validated for this antibody .

What considerations should be made when designing experiments to study temporal dynamics of PAR4 activation using this antibody?

To effectively study the temporal dynamics of PAR4 activation:

• Time-course design:

  • Include multiple time points after agonist application (30 seconds, 1, 2, 5, 10, 30 minutes)

  • Consider both rapid activation and potential desensitization phases

  • Include appropriate vehicle controls at each time point

• Agonist selection:

  • Compare thrombin vs. trypsin activation kinetics

  • Consider PAR4-specific peptide agonists vs. protease activation

  • Use appropriate concentrations of agonists to prevent receptor desensitization

• Subcellular localization:

  • Track receptor internalization following activation

  • Consider subcellular fractionation to detect cleaved receptors in different compartments

• Signal termination:

  • Study the half-life of the cleaved receptor

  • Investigate mechanisms of cleaved receptor degradation

• Relationship to downstream signaling:

  • Correlate receptor cleavage with calcium mobilization or phosphoinositide hydrolysis

  • Consider parallel measurements of G-protein activation

These approaches would provide comprehensive insights into the dynamics of PAR4 activation and signaling termination, areas that remain incompletely understood despite PAR4's important role in platelet function .